Professional Ethics and Responsibility-the Cipla Case Essay

854 Words May 14th, 2013 4 Pages
Professional Ethics and Responsibility

Firstly let us know what an intellectual property means? The property which an individual has is his inventions and creations and these his intellectual intellectual property is creation of mind let it be a symbol or a design or an artistic, literary work....

These properties can be categorized as;
• Industrial properties like patents, trademarks.
• Copyrights which mean the right to copy and use the literacy.artistic, musical works.

It is necessary to protect ones own individual ideas and everyone has a right to intellectual properties. So intellectual property rights are protected under the law and if any one feels that their patent or their
…show more content…
Cipla Pharmaceuticals' Yusuf Hamied stated: 'I Am Not Against Patents ... I Am Against Monopolies'

Cipla breached patent rights by slashing cancer drug price: Bayer Pharma

BERLIN: German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar.

Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company's decision to cut the price of the life-extending kidney and liver cancer drug "is a clear patent infringement," a Bayer spokesperson told.

Cipla had slashed the prices by up to 76 per cent of its generic drugs, used in treating cancers of brain, lung and kidney. The price of 'Soranib' used for treating kidney cancer was cut by 76 per cent to Rs 1,710 "for a month's therapy", from Rs 6,990, Cipla had said in a statement.
The Delhi High Court was dealing with a patent infringement suit filed by Bayer against the Indian company on March 15, 2010, in response to a decision of the Drug Controller General of India ( DCGI) to grant Cipla marketing authorisation for a generic version of Nexavar.

Bayer Pharma also confirmed that it has launched a legal challenge to the compulsory licence issued by India in March this year to domestic drugmaker Natco Pharma to manufacture and sell a low-cost generic copy of

Related Documents